NATCOPHARM Receives US FDA Tentative Approval for Olaparib Tablets

Lead

NATCOPHARM has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Olaparib tablets in 100 mg and 150 mg strengths. This approval confirms the bioequivalence of NATCOPHARM's product to AstraZeneca Pharmaceuticals' reference listed drug, Lynparza® tablets, for its approved labelling indication. The development marks a step forward for the company in potentially addressing a significant market, with estimated U.S. sales for Olaparib reaching approximately USD 1.4 billion for the twelve months ending March 2026.

Key highlights

• NATCOPHARM obtained tentative U.S. FDA approval for Olaparib tablets, 100 mg and 150 mg.
• The product is bioequivalent to AstraZeneca Pharmaceuticals' Lynparza® tablets.
• NATCOPHARM will be responsible for manufacturing the Olaparib tablets.
• Alembic Pharmaceuticals Limited will distribute the product in the U.S.
• Para IV litigation concerning Olaparib tablets remains ongoing.

What drove it

The exchange filing did not elaborate on the specific factors or internal processes that led to this particular tentative approval.

Context

NATCOPHARM's receipt of this tentative approval aligns with its stated strategy as an R&D-oriented, science-driven oncology player focusing on limited competition molecules within the U.S. market. The company has a history of pursuing and securing U.S. FDA approvals, including recent tentative approvals for other generic products such as Erdafitinib tablets (generic of Balversa®) in February 2026. This consistent pursuit underscores its strategic intent to expand its portfolio of generic pharmaceuticals in the United States, building on its nine manufacturing sites and two R&D facilities in India.

Why it matters

Receiving tentative U.S. FDA approval for Olaparib tablets is an important operational milestone for NATCOPHARM. It signifies that the company has met the stringent regulatory requirements for manufacturing and bioequivalence, positioning it for potential entry into the U.S. market once all legal and commercial hurdles are cleared. This could diversify NATCOPHARM's revenue streams and strengthen its presence in the oncology segment, an area where it positions itself as a leading player. The market size indicated by the estimated sales data suggests a substantial commercial opportunity.

What to watch

The resolution of the ongoing Para IV litigation will be a key factor determining the commercial launch timeline for NATCOPHARM's Olaparib tablets in the U.S. market. Future announcements from NATCOPHARM regarding the legal proceedings and any definitive approval or launch plans will provide further clarity. (Source: Exchange Filing NSE 106702629)